sC5b-9 Antibody (Monoclonal - neoantigen) , Biotinylated

A biotin conjugated murine monoclonal antibody to a neoantigen on the terminal complement complex.


Product Specifications

Citations 0
Clonality

Monoclonal

Immunogen Purified human protein.
Applications See citations and technical data sheet for application info.
Concentration 0.2 mg/mL
Conjugate Biotin
Cross Reactivity

Human, Baboon, Cynomologus macaque, Rhesus macaque.

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A711
Catalog Number (CE) N/A
Size 250 µL
Price (USD) $365.00
Price (EURO) 330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A biotin conjugated murine monoclonal antibody to a neoantigen on the terminal complement complex.

Size 250 µL
Concentration

0.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Phosphate Buffered Saline (pH 7.0 ± 0.2), 1% Bovine Serum Albumin, with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Biotin
Cross Reactivity Human, Baboon, Cynomologus macaque, Rhesus macaque.
Isotype IgG2bk
Purity ≥ 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC.

Citations

Title Year Applications Sample Species Sample Sample Details